8-K: Health Catalyst Reports Q1 2026 Results, Exceeding Expectations

Health Catalyst announced first quarter 2026 financial results, with revenue and adjusted EBITDA surpassing expectations, alongside a strategic operating model transformation.

Summary

• Health Catalyst reported first quarter 2026 results with total revenue of $70.76 million, a decrease of 11% year-over-year.
• Gross profit was $27.73 million, down 3% year-over-year, but gross margin improved to 39% from 36% in the prior year.
• Adjusted EBITDA showed significant growth, increasing by 46% year-over-year to $9.14 million.
• The company reported a net loss of $111.03 million for the quarter, a substantial increase from the $23.74 million net loss in Q1 2025, largely due to a $95.5 million goodwill impairment.
• For the second quarter of 2026, Health Catalyst anticipates total revenue between $68 million and $70 million, and Adjusted EBITDA between $9 million and $10 million.
• Full-year 2026 guidance projects total revenue of $260 million to $265 million and Adjusted EBITDA of $30 million to $33 million.
• The company is undertaking a strategic reset of its operating model to focus on its highest-conviction technology opportunities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed signal; while operational metrics like Adjusted EBITDA exceeded expectations and a strategic reset is underway, the significant revenue decline, widening net loss, and goodwill impairment present considerable headwinds.

Positives

• Revenue and Adjusted EBITDA exceeded expectations for the first quarter of 2026.
• Adjusted EBITDA increased by 46% year-over-year to $9.14 million.
• Gross margin improved to 39% from 36% in the prior year's first quarter.
• The company is implementing a strategic reset to focus on core technology opportunities, aiming for a more focused and durable business.
• The company has documented $2.8 billion in outcomes.

Negatives

• Total revenue decreased by 11% year-over-year to $70.76 million.
• Gross profit decreased by 3% year-over-year to $27.73 million.
• Net loss widened significantly to $111.03 million from $23.74 million in the prior year's quarter.
• A substantial goodwill impairment of $95.5 million was recorded in the quarter.
• The company is experiencing potential churn or down-sell in Annual Recurring Revenue (ARR) related to the DOS to Ignite migration, impacting 2026 and 2027.

Risks

• Changes in laws and regulations applicable to the business model.
• Changes in market or industry conditions, regulatory environment, and receptivity to technology and services.
• Results of litigation or a security incident.
• Loss of key clients or partners, clients reducing spend, or client churn/down-sell in connection with the DOS to Ignite migration.
• Fluctuations in project-based, non-recurring revenue.
• Macroeconomic challenges, including high inflation, high interest rates, tariffs, market volatility, natural disasters, public health crises, and regional or global conflicts.
• Changes to the ability to recruit and retain qualified team members.

Future Outlook

For the second quarter of 2026, Health Catalyst expects total revenue between $68 million and $70 million, and Adjusted EBITDA between $9 million and $10 million. For the full year 2026, the company projects total revenue of $260 million to $265 million and Adjusted EBITDA of $30 million to $33 million.

Management Comments

• "We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations."
• "More importantly, this quarter we took the first decisive step toward transforming our operating model and aligning the company around its highest-conviction technology opportunities."
• "This is not a short-term cost exercise. It is a strategic reset designed to build a more focused, durable Health Catalyst capable of meeting the opportunity in front of us."
• "I am confident in the leadership team and board we have assembled to build the intelligence-driven technology company healthcare needs."

Industry Context

StockSavvy.ai notes that Health Catalyst's strategic pivot towards a more focused operating model aligns with broader industry trends of specialization and efficiency in the healthcare technology sector, especially in light of increasing market pressures and the need for demonstrable ROI.

Comparison to Industry Standards

• The reported Adjusted EBITDA of $9.14 million for Q1 2026 shows a 46% year-over-year increase, indicating strong operational leverage and efficiency gains, which is a positive trend compared to some peers facing slower growth.
• The gross margin improvement to 39% (GAAP) and 51% (Adjusted) is a positive sign, though overall revenue decline of 11% warrants attention. Industry benchmarks for SaaS companies in healthcare can vary, but margin expansion alongside revenue contraction often signals cost management or a shift in product mix.
• The significant net loss and goodwill impairment highlight challenges in integrating past acquisitions or market shifts impacting asset valuations, a concern that some competitors in the health tech space have also faced.

Stakeholder Impact

• Shareholders: The widening net loss and goodwill impairment may be concerning, but exceeding EBITDA expectations and a strategic focus could be viewed positively for long-term value.
• Employees: The strategic reset and focus on technology opportunities may lead to shifts in roles and responsibilities, with potential implications from workforce reductions mentioned in restructuring costs.
• Customers: The DOS to Ignite migration presents a risk of churn or down-sell, potentially impacting customer relationships and service continuity if not managed effectively.

Next Steps

• Continue execution of the strategic operating model transformation.
• Focus on highest-conviction technology opportunities.
• Monitor and manage potential ARR churn related to the DOS to Ignite migration.
• Report Q2 2026 financial results and provide updated guidance.

Key Dates

Recommendation

The company is at a critical juncture with a strategic reset underway. While Q1 results exceeded expectations on key non-GAAP metrics like Adjusted EBITDA, the significant year-over-year revenue decline, substantial net loss, and goodwill impairment are serious concerns. The potential for customer churn related to the DOS to Ignite migration adds further uncertainty. A 'hold' recommendation is appropriate pending clearer evidence of the success of the strategic transformation and stabilization of revenue and profitability.

Keywords

Health Catalyst, HCAT, Healthcare Intelligence, Q1 2026 Earnings, Adjusted EBITDA, Revenue, Goodwill Impairment, Strategic Reset